Dear Editors, Serotonin syndrome (SS) is a rare and potential ly life-threaten ing condition. It results from exces sive serotonin eff ect on the central and peripheral nervous system. Serotonin (5-HT) is an excitatory neurotransmitter involved in the regulation of wakefulnes s, aff ective behaviour, and regulation of autonomic functions such as vascular tone, gastrointestinal motility and thermoregulation [1, 2] .
The onset of SS ranges from several hours to several weeks after the administration of serotonergic drugs (Tab. 1). SS is diffi cult to detect as the signs can run from mild to lifethreaten ing symp toms involv ing mental status changes (anxiety, agitation, visual hallucinations, restles snes s, disorientation and coma), autonomic instability (hyper-/ hypotension, tachycardia, tachypnea, diar rhea, mydriasis, hyperthermia) and neuromuscular hyperactivity (muscle rigidity, tremors, nystagmus, myoclonus, ocular clonus, hyper reflexia). Several dia gnostic criteria have been published (Sternbach's Criteria, Radomski's Criteria and more sensitive and specifi c Hunter's Criteria in Tab. 2). The seven clinical features are as sociated with serotonin toxicity: clonus, agitation, diaphoresis, tremor, hyper refl exia and hypertonicity with temperature > 38 °C [2] [3] [4] . Mild symp toms usual ly resolve within 24 hours of ces sation of the serotonergic drugs. Severe cases may manifest as severe hyperthermia, seizure, rigidity, respiratory ar rest, or even death [1, 5] .
No specifi c laboratory abnormality is diagnosed in SS. The blood level of serotonin does not cor relate with the severity of the condition as it does not refl ect the intrasynaptic serotonin level. In cases of severe serotonin toxicity with muscular hypertonicity and rhabdomyolysis we can observe electrolyte derangements, metabolic acidosis, elevated creatinine levels and increased serum aminotransferase [4, 6] .
Selective serotonin reuptake inhibitors (SSRI) are the most frequently reported drugs as sociated with SS. When SS is recognised, im mediate withdrawal of the causative drug is neces sary. Supportive care is the mainstay of the treatment. Anxiety and agitation can be managed with benzodiazepines and serotonin symp toms can be managed with the 5-HT1A/ 2A receptor antagonist cyproheptadine or chlorpromazine. Severe cases of hyperthermia may require neuromuscular paralysis and intubation. Antipyretic agents do not help, because hyperthermia is caused by muscle hypermetabolism. Only early dia gnosis and treatment can prevent complications such as the development of multiple organ dysfunction syndrome and death [1, 2, 6] .
A 51-year-old female was presented to our emergency department early in the morn ing for dyspnoea, signifi cant arthralgia, psychomotor unrest, and tremor. Physical examination showed mydriasis, tachycardia (110/ min), arterial hypertension (160/ 100 m m Hg), elevated respiratory rate (24/ min) and raised temperature (39 °C). Accord ing to the medical history, the patient had been repeatedly prescribed analgesic drugs (meloxicam, indomethacin and tramadol). She had asthma bronchiale treated with the inhaled corticosteroid budesonide in fi xed combination with formoterol (160/ 4.5 mg). Further medication of the patient included ivabradine (10 mg/ d) for sinus tachycardia, psychiatric medications paroxetine (60 mg/ d), trazodone (300 mg/ d), chlorprothixen (50 mg/ d) and bromazepam (2 mg/ d). Accord ing to the patient's medical history confi rmed lately by a family member, the patient was virtual ly housebound due to pain. She combined various analgesics and antidepres sants, 2 days before admis sion she had even increased doses by herself. Dur ing the examination, the patient suff ered from a col lapse. An electromechanical dissociation was dia gnosed and cardiopulmonary resuscitation (CPR) was initiated (lasting for 5 min). Severe metabolic acidosis was found. A nasogastric tube was pas sed and showed the presence of a variety of drugs in the stomach contents. Samples for toxicological test ing were sent. The electrocardiography (ECG) showed 0.5-mm ST segment depres sion in I and aVL leads. Computed tomography (CT) of the chest was negative for pulmonary embo lisms, while CT of the brain demonstrated an oedema.
The patient was admitted to the intensive care unit (ICU) after CPR for asystole of unclear aetiology. On admis sion, sedation (sufentanil, midazolam) and artificial pulmonary ventilation were started and rescue ther apy was initiated. We observed significant circulatory instability combined with SEVERE SEROTONIN SYNDROME Cesk Slov Ne urol N 2017; 80/ 113(6): 711-713 sinus tachycardia (up to 160/ min) and administered high doses of norepinephrine and esmolol. The level of leukocytes was 20,000. Blood and urine samples were sent for cultivation. Additional ly, antimicrobial agents were adminis tered (levofl oxacin, piperacillin/ tazobactam) and anti-oedematous therapy (osmother apy with 10% NaCl) was applied to reduce cerebral oedema. Facial myoclonus was observed as well as subsequent spasms of the entire body. Electroencephalography (EEG) revealed nonspecifi c epileptic graphoelements. Higher doses of benzodiazepines (midazolam 15 mg/ h) were required to manage persist ing generalized myoclonus. A neuro-block ing agent -cisatracurium (20 mg) -was administered due to the interference with artifi cial ventilation. The initial pH after admis sion to our ICU was 7.1, BE 14.6 with lactate 20 m mol/ l. We started with diff erential dia gnosis of severe metabolic acidosis. Test ing for ethanol, methanol and ketones showed negative results, renal functions were normal. Toxicological test ing for antidiabetic drugs was negative, but the presence of many substances: analgesic drugs (codeine, tramadol, meloxicam and acetaminophen), antidepres sants (trazodone, paroxetine), anxiolytic drugs (hydroxyzine, midazolam) and chlorprothixen, was confirmed. The patient was continuously febrile, requir ing sedation (midazolam 10-15 mg/ h and sufentanil 10 μg/ h) and physical cooling, but the eff ect was disputable. Antipyretics (acetaminophen, 4 g/ day) were ineff ective.
By day 2, the patient's serum laboratory fi ndings showed an increased leucocytosis (30,000). She developed oliguria, serum myoglobin levels reached 14.434 mg/ l during the day, and therefore, continuous renal replacement ther apy (CRRT) was initiated.
The laboratory evaluation excluded a systemic dis ease. She developed pneumonia (Candida albicans and Aspergilus fumigatus) and voriconazole was added to the treatment.
By day 4, her white blood cell count started to decrease, the metabolic acidosis resolved, but myoglobinaemia decreased only slowly. However, the patient's circulatory system was still unstable. A transcranial Doppler (TCD) showed no signs of intracranial hypertension. Electroencephalography was performed repeatedly, generalized triphasic waves were observed, but without specifi c epileptic discharges (Fig. 1) . Tracheostomy was performed and sedation was subsequently reduced. Final ly, on day 5-serotonin syndrome was dia gnosed in co-operation with clinical pharmacologist and neurologists. The clinical triad characteristic for SS was confi rmed: mental changes prior to sedation (agitation, delirium), vegetative instability (sweating, fever, tachycardia) and myoclonus accompanied by rhabdomyolysis and muscular rigidity. New potential serotonergic drugs were stopped (opioid agent sufentanil and prokinetic agent metoclopramide, antibio tic levofl oxacin-inhibitor CYP3A4), benzodiazepines continued and anti-serotonergic ther apy (chlorpromazine plus cyproheptadine) were initiated. An initial dose of 12 mg of cyproheptadine was administered and then 2 mg every 2 h to a max. dose of 32 mg/ day. Maintenance dos ing of 8 mg every 6 h was administered on the fol low ing days. The patient's clinical condition improved. However, the long-term prognosis was very unfavourable and 16 days later the patient appeared as coma vigil.
Severe SS toxicity may develop into a life-threaten ing condition with muscular rigidity, hyperthermia and coma. Symptoms with escalat ing toxicity, if left untreated, may result in complications includ ing metabolic acidosis, rhabdomyolysis, disseminated intravascular coagulation, seizures and death [2] . The case report detailed above is an example of a severe case of SS which developed into coma vigil due to an untimely dia gnosis of the condition. The patient's medical history as well as serum toxicological analysis revealed the presence of several serotonergic drugs, antidepres sants (trazodone, paroxetine) and analgesics (tramadol, codeine) [3, 4] . Antidepres sants may be the most com monly implicated drugs associated with SS [7] [8] [9] . The lack of monitoring of the potential iatrogenic adverse in- Tab. 2. Hunter's Serotonin Toxicity Criteria (sensitivity 84%, specifi city 97%).
In the presence of a serotoninergic agent, any one of: teractions was a signifi cant factor for the untimely dia gnosis of SS. The presented case demonstrates the necessity to consider drug interactions. It is highly chal leng ing for clinicians to identify thera peutic combinations that may increase the risk of SS. Serotonin toxicity presents as a triad of symptoms of mental-status changes, autonomic hyperactivity and neuromuscular abnormalities. Early recognition of SS and discontinuation of off end ing drugs are vital for succes sful management of this serious adverse reaction.
